May 20 |
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer
|
May 10 |
eFFECTOR Therapeutics GAAP EPS of -$2.16 beats by $0.01
|
May 9 |
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
Apr 9 |
eFFECTOR Therapeutics to Participate in Upcoming Investor Conference
|
Apr 4 |
eFFECTOR stock slides on decision to discontinue development of tomivosertib for lung cancer treatment
|
Apr 4 |
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
|
Mar 25 |
eFFECTOR Therapeutics GAAP EPS of -$3.42, revenue of $0M
|
Mar 25 |
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
Feb 5 |
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
|
Jan 29 |
eFFECTOR Therapeutics Announces Closing of $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
|